These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28922411)

  • 1. Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus.
    Zhao X; Ouyang W; Chester C; Long S; Wang N; He Z
    PLoS One; 2017; 12(9):e0184816. PubMed ID: 28922411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.
    Prestwich RJ; Ilett EJ; Errington F; Diaz RM; Steele LP; Kottke T; Thompson J; Galivo F; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
    Clin Cancer Res; 2009 Jul; 15(13):4374-4381. PubMed ID: 19509134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model.
    Yang Z; Zhang Q; Xu K; Shan J; Shen J; Liu L; Xu Y; Xia F; Bie P; Zhang X; Cui Y; Bian XW; Qian C
    PLoS One; 2012; 7(9):e44802. PubMed ID: 23028626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.
    Parrish C; Scott GB; Migneco G; Scott KJ; Steele LP; Ilett E; West EJ; Hall K; Selby PJ; Buchanan D; Varghese A; Cragg MS; Coffey M; Hillmen P; Melcher AA; Errington-Mais F
    Leukemia; 2015 Sep; 29(9):1799-810. PubMed ID: 25814029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.
    Jennings VA; Ilett EJ; Scott KJ; West EJ; Vile R; Pandha H; Harrington K; Young A; Hall GD; Coffey M; Selby P; Errington-Mais F; Melcher AA
    Int J Cancer; 2014 Mar; 134(5):1091-101. PubMed ID: 23982804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reovirus activates human dendritic cells to promote innate antitumor immunity.
    Errington F; Steele L; Prestwich R; Harrington KJ; Pandha HS; Vidal L; de Bono J; Selby P; Coffey M; Vile R; Melcher A
    J Immunol; 2008 May; 180(9):6018-26. PubMed ID: 18424722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells.
    Osali A; Zhiani M; Ghaebi M; Meymanat M; Esmaeilzadeh A
    Pharmacol Res; 2020 Nov; 161():105094. PubMed ID: 32795509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.
    Sampath P; Li J; Hou W; Chen H; Bartlett DL; Thorne SH
    Mol Ther; 2013 Mar; 21(3):620-8. PubMed ID: 23229093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.
    Ilett EJ; Bárcena M; Errington-Mais F; Griffin S; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Limpens RW; Mommaas M; Hoeben RC; Vile RG; Melcher AA
    Clin Cancer Res; 2011 May; 17(9):2767-76. PubMed ID: 21389099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.
    Ilett E; Kottke T; Donnelly O; Thompson J; Willmon C; Diaz R; Zaidi S; Coffey M; Selby P; Harrington K; Pandha H; Melcher A; Vile R
    Mol Ther; 2014 Oct; 22(10):1851-63. PubMed ID: 24957982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model.
    Yan Y; Xu Y; Zhao Y; Li L; Sun P; Liu H; Fan Q; Liang K; Liang W; Sun H; Du X; Li R
    Tumour Biol; 2014 Feb; 35(2):1113-22. PubMed ID: 24037896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Pyruvate Dehydrogenase Kinase Enhances the Antitumor Efficacy of Oncolytic Reovirus.
    Kennedy BE; Murphy JP; Clements DR; Konda P; Holay N; Kim Y; Pathak GP; Giacomantonio MA; Hiani YE; Gujar S
    Cancer Res; 2019 Aug; 79(15):3824-3836. PubMed ID: 31088833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stem cells loaded with oncolytic reovirus enhances antitumor activity in mice models of colorectal cancer.
    Babaei A; Soleimanjahi H; Soleimani M; Arefian E
    Biochem Pharmacol; 2021 Aug; 190():114644. PubMed ID: 34090878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
    Rodríguez Stewart RM; Berry JTL; Berger AK; Yoon SB; Hirsch AL; Guberman JA; Patel NB; Tharp GK; Bosinger SE; Mainou BA
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of oncolytic reovirus against human gastric cancer with peritoneal metastasis in experimental animal model.
    Kawaguchi K; Etoh T; Suzuki K; Mitui MT; Nishizono A; Shiraishi N; Kitano S
    Int J Oncol; 2010 Dec; 37(6):1433-8. PubMed ID: 21042711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.
    Adair RA; Roulstone V; Scott KJ; Morgan R; Nuovo GJ; Fuller M; Beirne D; West EJ; Jennings VA; Rose A; Kyula J; Fraser S; Dave R; Anthoney DA; Merrick A; Prestwich R; Aldouri A; Donnelly O; Pandha H; Coffey M; Selby P; Vile R; Toogood G; Harrington K; Melcher AA
    Sci Transl Med; 2012 Jun; 4(138):138ra77. PubMed ID: 22700953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of Genetically RGD σ1-Modified Oncolytic Reovirus That Enhances JAM-A-Independent Infection of Tumor Cells.
    Kawagishi T; Kanai Y; Nouda R; Fukui I; Nurdin JA; Matsuura Y; Kobayashi T
    J Virol; 2020 Nov; 94(23):. PubMed ID: 32907973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.
    Thirukkumaran CM; Nodwell MJ; Hirasawa K; Shi ZQ; Diaz R; Luider J; Johnston RN; Forsyth PA; Magliocco AM; Lee P; Nishikawa S; Donnelly B; Coffey M; Trpkov K; Fonseca K; Spurrell J; Morris DG
    Cancer Res; 2010 Mar; 70(6):2435-44. PubMed ID: 20215509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling.
    McEntee G; Kyula JN; Mansfield D; Smith H; Wilkinson M; Gregory C; Roulstone V; Coffey M; Harrington KJ
    Oncotarget; 2016 Jul; 7(30):48517-48532. PubMed ID: 27384486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.